ImmVira grabs Series C

ImmVira Group Company, a a biotechnology platform focused on developing therapies against cancer, has secured Series C financing.

ImmVira Group Company, a a biotechnology platform focused on developing therapies against cancer, has secured Series C financing. No financial terms were disclosed. The investors included Greater Bay Area Homeland Development Fund, Octagon Capital, China Merchants Capital, WinDigital Capital, LanTing Capital and OrbiMed.

Source: Press Release